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Activated Mutant NRasQ61K Drives Aberrant
Melanocyte Signaling, Survival, and Invasiveness
via a Rac1-Dependent Mechanism
Ang Li1, Yafeng Ma1, Meng Jin1, Susan Mason1, Richard L. Mort2, Karen Blyth1, Lionel Larue3,
Owen J. Sansom1 and Laura M. Machesky1
Around a fifth of melanomas exhibit an activating mutation in the oncogene NRas that confers constitutive
signaling to proliferation and promotes tumor initiation. NRas signals downstream of the major melanocyte
tyrosine kinase receptor c-kit and activated NRas results in increased signaling via the extracellular
signal–regulated kinase (ERK)/MAPK/ERK kinase/mitogen-activated protein kinase (MAPK) pathways to enhance
proliferation. The Ras oncogene also activates signaling via the related Rho GTPase Rac1, which can mediate
growth, survival, and motility signaling. We tested the effects of activated NRasQ61K on the proliferation, motility,
and invasiveness of melanoblasts and melanocytes in the developing mouse and ex vivo explant culture as well
as in a melanoma transplant model. We find an important role for Rac1 downstream of NRasQ61K in mediating
dermal melanocyte survival in vivo in mouse, but surprisingly NRasQ61K does not appear to affect melanoblast
motility or proliferation during mouse embryogenesis. We also show that genetic deletion or pharmacological
inhibition of Rac1 in NRasQ61K induced melanoma suppresses tumor growth, lymph node spread, and tumor
cell invasiveness, suggesting a potential value for Rac1 as a therapeutic target for activated NRas-driven tumor
growth and invasiveness.
Journal of Investigative Dermatology (2012) 132, 2610–2621; doi:10.1038/jid.2012.186; published online 21 June 2012
INTRODUCTION
Mutations in the Ras proto-oncogene family (HRas, NRas,
and KRas) are among the most frequently mutated genes in
human cancers, occurring in 20–30% of human tumors
(Downward, 2003). Residue G12 in the phosphate-binding
loop and the catalytic residue Q61 are most commonly
mutated (Malumbres and Barbacid, 2003). Constitutively
active NRasQ61K is frequently found in nevi and early-stage
melanomas (Platz et al., 2008). Expression of human
NRasQ61K in the mouse melanocyte lineage results in
hyperpigmented skin (Ackermann et al., 2005), which can
progress to cutaneous melanoma on an INK4a-deficient
background.
The mitogen-activated protein kinase pathway, modulated
by Raf directly interacting with Ras, is a key downstream
effector in Ras signaling (Cook and McCormick, 1994;
Marshall, 1995; Gray-Schopfer et al., 2007). However, the
recruitment of other Ras targets is indispensable to elicit a full
Ras biological response. Among these Ras-dependent, Raf-
independent pathways are those connecting Ras to the Rho
subfamily of small GTPases. There are no published reports of
activating Rho-family mutations in human tumors, but Rho-
family proteins often exhibit upregulation of their activity in
tumors (Sahai and Marshall, 2002).
The small GTPase Rac1 is required for cell cycle regulation
and Ras-induced transformation in vitro (Qiu et al., 1995), but
relatively little is known about its role in cancer in vivo. Rac1
is required for KRasG12D-driven formation of lung tumors
(Kissil et al., 2007) and oral papillomas (Samuel et al., 2011).
However, activated Ras isoforms can exert profoundly
different effects in different forms of cancer (Hancock, 2003;
Whitwam et al., 2007; Karreth and Tuveson, 2009). Here, we
show that Rac1 activity is required for NRasQ61K-induced
dermal melanocyte survival in vivo and for increased
invasiveness conferred by NRasQ61K on primary melanocytes
in vitro and in vivo. In addition, genetic deletion or
pharmacological inhibition of Rac1 in NRasQ61K-expressing
melanoma tumors suppressed tumor growth and lymph node
spread. Thus, many of the crucial downstream effects of
NRasQ61K in melanoma are likely to be mediated by Rac1 and
implicate Rac1 and its downstream partners as potential key
targets for melanoma therapy.
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RESULTS
Rac1 is required for anchorage-independent growth (AIG) of
NRasQ61K-expressing primary murine melanocytes in culture
In our recent study (Li et al., 2011), we generated two
independent immortalized Rac1 f/f Ink4a/ TyrHCreERt2þ /o
melanocyte cell lines #3 and #4, which were unable to grow
in soft agar (Figure 1c–e). To test the importance of Rac1
downstream of NRasQ61K in oncogenic transformation for
melanocytes, we generated melanocyte cell lines from 1-day-
old TyrHNRasQ61Kþ /o Rac1 f/f Ink4/ TyrHCreERt2þ /o (#10
and #11) and TyrHNRasQ61Kþ /o Rac1 f/f Ink4a/ TyrH-
CreERt2o/o (#5) littermate mice (also littermate of #3 and #4).
As expected, NRasQ61Kþ /o-expressing melanocytes (#5, #10
and #11) have elevated activation of mitogen-activated
protein kinase signaling compared with Rac1 f/f Ink4a/
TyrHCreERt2þ /o melanocyte cell lines #3 and #4 (Figure 1a;
Ackermann et al., 2005; Whitwam et al., 2007; Li et al.,
2011), but Rac1 expression level was not affected by
expression of NRasQ61K (Figure 1a). Rac1 deletion was
induced with tamoxifen analog 4-hydroxytamoxifen (OHT)
in cell lines that express CreERt2 (#10 and #11), but not in cell
line #5, which is CreERt2 negative (Figure 1b). Neither Rac2
nor Rac3 was detectable, regardless of Rac1 deletion (Figure
1b). All the NRasQ61K-expressing melanocyte cell lines (#5,
#10 and #11) were able to induce rapid AIG in soft agar and
form large colonies (Figure 1c–e). Rac1 deletion reduced
colony number by about 80% and the average colony size by
about 60% (Figure 1c–e). Rac1-deleted NRasQ61K-expressing
melanocytes additionally showed reduced proliferation (Sup-
plementary Figure S1A online). 12-O-Tetradecanoylphorbol
13-acetate acts as a growth factor for cultured melanocytes,
but is not required for growth when melanocytes are
transformed by constitutively active c-kit receptor (Larue
et al., 1992). Similarly, 12-O-tetradecanoylphorbol 13-acetate
is not required for NRasQ61K-expressing melanocytes growth
on either 2D or in soft agar (Supplementary Figure S1 online).
Thus, NRasQ61K confers Rac1-dependent AIG on primary
melanocytes. This suggests an important, but previously
undescribed, role for Rac1 in mediating oncogenic transfor-
mation induced by NRasQ61K in melanocytes.
NRasQ61K does not confer excess melanocyte accumulation in
embryos, but loss of Rac1 leads to melanocyte proliferation
defects
We next examined the number and position of melanoblasts in
TyrHNRasQ61K-expressing embryos. Strikingly, TyrHNRasQ61K-
expressing E15.5 embryos or P0.5 newborn pup skin did not
show a statistically significant increase in the number of
melanoblasts/melanocytes (Supplementary Figure S2 online).
There was a significant reduction in melanoblast number in
Rac1 f/f TyrHCre embryos regardless of the presence of
TyrHNRasQ61K (Supplementary Figure S2 online), indicating
that NRasQ61K does not affect melanoblast numbers or position.
Expression of NRasQ61K causes Rac1-dependent
hyperpigmentation in adult mice
Mice of the C57BL/6 strain normally have light skin and black
fur, but when TyrHNRasQ61K is expressed, they have black
skin and darker fur (Ackermann et al., 2005). Mice lacking
Rac1 in melanocytes have white patches on the underside
and along the dorsal midline and also a lightening of the
paws and tails (Supplementary Figure S2C and D online; Li
et al., 2011). At P14, TyrHNRasQ61K Rac1 f/f TyrHCre mice
had similar pigmentation patterns to Rac1 f/f TyrHCre mice
(Figure 2a–d and Supplementary Figure S3A and B online;Li
et al., 2011). Furthermore, the number and size of white
patches on the dorsal skin between TyrHNRasQ61K Rac1 f/f
TyrHCre and Rac1 f/f TyrHCre mice was similar (Figure 2a
and e and Supplementary Figure S3A online). Mice were
born healthy at the expected Mendelian ratio. However,
TyrHNRasQ61K Rac1 f/f TyrHCre mice were smaller than
control littermates and had a similar weight to Rac1 f/f
TyrHCre as measured on P7 and P14 (Figure 2f and g and
Methods). Histological analysis of P14 TyrHNRasQ61K
ventral skin revealed melanocytes in hair follicles, dermis
and fatty tissue (Figure 2h). Thus, deletion of Rac1 in the
melanocyte lineage from mice expressing NRasQ61K re-
sulted in similar pigmentation defects as Rac1 deletion
alone.
Expression of NRasQ61K promotes survival and accumulation of
epidermal/dermal melanocytes via Rac1 over the hair cycle
Before birth, murine melanoblasts reside in the dermis and
epidermis (Luciani et al., 2011), but shortly after birth they
reside only in hair follicles (Kelsh et al., 2009). We
investigated the origin of TyrHNRasQ61K dermal melanocyte
clusters (Figure 2h, arrow) and the effect of Rac1 loss during
the first hair cycle, which is synchronous (Fuchs, 2007).
Dorsal skin from control, TyrHNRasQ61K control, Rac1 f/f
TyrHCre and TyrHNRasQ61K Rac1 f/f TyrHCre mice at P0.5,
3, 5, 14, and 21 was sectioned and stained with dopachrome
tautomerase antibody to localize melanocytes. In control,
Rac1 f/f TyrHCre and TyrHNRasQ61K Rac1 f/f TyrHCre mice,
melanocytes in epidermis and dermis gradually disappeared
from P0.5 to P5 (Figure 3a, Supplementary Figure S4A and C
online and data not shown), leaving only hair follicle
melanocytes (Hirobe, 1984; Kelsh et al., 2009). However,
in TyrHNRasQ61K control mice, melanocytes in epidermis
survived from P0.5 and number of melanocytes in epidermis
increased over the hair cycle (Figure 3a, Supplementary
Figure S4B online), indicating that expression of NRasQ61K
promotes Rac1-dependent postnatal melanocyte survival
and/or growth in epidermis.
At P14, TyrHNRasQ61K control (Figure 3c) and TyrHN-
RasQ61K Rac1 f/f TyrHCre (Figure 3d) skin showed excess
melanocytes in hair follicles (Figure 3b). However, in
TyrHNRasQ61K control mice, melanocytes also accumulated
in clusters in the epidermis/dermis and fatty tissue (Figure 3c,
arrows) but these were absent from TyrHNRasQ61K Rac1 f/f
TyrHCre mice (Figure 3d and e).
The transition from anagen to telogen leads to apoptosis of
most follicular melanocytes (Sharov et al., 2005). In the
telogen phase of the first hair follicle cycle (P21), only the
permanent part of the hair follicles remained in dorsal skin
taken from control mice (Supplementary Figure S4A online).
Most of follicular melanocytes remained in the dermis even
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after the hair follicles in TyrHNRasQ61K mouse degenerated
(Figure 3f and Supplementary Figure S4B online, arrows).
Which, however, failed to be maintained when Rac1 was
deleted (Figure 4f, Supplementary Figure S4C online). Thus,
NRasQ61K protects dermal melanocytes from being cleared
from the skin in a Rac1-dependent manner.
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Figure 1. Rac1 is required for NRasQ61K-induced anchorage-independent growth. (a) Western blots of primary melanocyte cell lines with antibodies as
indicated. (b) Western blot of #5, #10, and #11 primary melanocyte cell lines treated with DMSO or 4-hydroxytamoxifen (OHT) for 5 days were probed with
antibodies as indicated. (c) Representative images of primary melanocyte cell lines treated with DMSO or OHT were plated in soft agar in the presence of 200 nM
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NRasQ61K does not affect the motility of melanoblasts in
embryonic skin or their ability to cross the embryonic dermal/
epidermal basement membrane
Melanoma metastasis has analogies with embryonic develop-
ment (Hendrix et al., 2007; Yang and Weinberg, 2008).
NRasQ61K is frequently found in human metastatic melanoma
(Demunter et al., 2001), thus may contribute to abnormal
invasiveness and migration of melanoma cells (Mishra et al.,
2010). We studied the motility of melanoblasts in the
epidermis of embryo skin explants by live imaging (Mort
et al., 2010). We asked whether NRasQ61K could affect
melanoblast motility and whether this was Rac1 dependent,
as Rac1 is important for speed and protrusion formation of
melanoblasts (Li et al., 2011). Melanoblasts expressing
NRasQ61K had a similar morphology to control melanoblasts,
showing both long and short protrusions (Figure 4a) in the
same proportions (Figure 4g and h). NRasQ61K-expressing
melanoblasts extended dynamic short protrusions that elon-
gated and often dictated the direction of migration (Figure 4c
yellow arrows and Supplementary Movie S1 online). Loss of
Rac1 in NRasQ61K-expressing melanoblasts produced a
phenotype indistinguishable from Rac1 null melanoblasts,
with short stubby protrusions leading migration but rarely
elongating (Figure 4c, yellow arrows, Supplementary Movie S1
online). Furthermore, by labeling melanoblasts with lifeact-
GFP (Li et al., 2011), we also confirmed that the short stubby
protrusions in TyrHNRasQ61K Rac1 f/f TyrHCre melanoblasts
were actin-rich spiky protrusions and not bleb-based (Figure
4d, yellow arrows, Supplementary Movie S2 online). Expres-
sion of activated NRasQ61K did not measurably affect the
migration speed (Figure 4b and e), persistence (Figure 4f),
lifetime (Figure 4i), or frequency of protrusions (Figure 4j).
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Therefore, we conclude that NRasQ61K does not affect
melanoblast motility in any detectable way. Furthermore,
there was no effect of expression of NRasQ61K on the ratio of
melanoblasts in the dermis versus epidermis (Figure 4k and l).
In summary, NRasQ61K expression has no detectable effect on
melanoblast motility or basement membrane crossing during
embryogenesis, whereas signaling through Rac1 is limiting for
melanoblast proliferation and motility.
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Rac1 is required for NRasQ61K-induced invadopodia formation
and invasion
We asked whether expression of NRasQ61K could enhance
the ability of melanocytes to degrade extracellular matrix and
whether matrix-remodeling capacity was Rac1 dependent.
Invadopodia are actin-based membrane protrusions formed
in invasive cancer cells that have a matrix degradation
activity (Buccione et al., 2004). They are rich in filamentous
actin, cortactin, and Arp2/3 complex (Linder, 2007). To
examine whether NRasQ61K could induce invadopodia
formation, wild-type melanocyte cell lines (#3 and #4) and
NRasQ61K melanocyte cell lines (#10 and #11) were cultured
on cross-linked gelatin matrix. Wild-type melanocytes (#3
and #4) showed similar morphology compared with
NRasQ61K-expressing melanocyte cell lines, but did not
display invadopodia (Figure 5a). In contrast, NRasQ61K-
expressing melanocyte cell lines (#5, #10 and #11) formed
copious invadopodia (Figure 5b). We found B45% of
NRasQ61K-expressing melanocytes and only 4% of normal
melanocytes contained invadopodia (Figure 5c). Further-
more, the matrix degradation for individual cells was
negligible in controls (#3 and #4) as compared with
NRasQ61K-expressing melanocytes (Figure 5d).
#10 and #11 NRasQ61K-expressing melanocytes treated
with OHT to induce Rac1 deletion showed about 60%
reduction in the percentage of cells degrading matrix (Figure
5c) and 80% reduced degradation (Figure 5a and e). OHT
treatment did not affect invadopodia formation by #5
melanocytes, which do not delete Rac1 (Figure 5d). In
addition, OHT-treated #10 and #11 melanocytes failed to
invade in organotypic assays (Figure 5f and g). We conclude
that Rac1 is important for melanocyte invadopodia formation
and invasion downstream of NRasQ61K.
Genetic deletion or pharmacological inhibition of Rac1 impairs
NRasQ61K-induced melanoma tumor growth and formation of
lymph node metastasis
Although Rac function is required for KRasG12D-induced
primary squamous cell skin and lung tumor initiation (Kissil
et al., 2007; Samuel et al., 2011), the role of Rac1 in
NRasQ61K-induced tumor growth and invasiveness in vivo
has not been addressed. We transplanted #11 NRasQ61K Rac1
f/f melanocytes subcutaneously into the left flank of nude
mice (CD-1). The growth of Rac1-deleted allografts on day
1–3 of tamoxifen treatment was similar to vehicle, likely
because it requires 3 days to deplete endogenous Rac1 (Li
et al., 2011). However, allograft growth halted at day 5 after
tamoxifen treatment (Figure 6a). BrdU incorporation was
reduced by 60% in Rac1-deleted allografts (Figure 6b and c).
Pak2 (Mouse melanocytes do not express Pak1/3 (Li et al.,
2011).), Erk1/2, and AKT activation were reduced in Rac1-
deleted allografts. Although the other Rac1-dependent
signaling pathways (JNK, p38, and NF-kB; Jaffe and Hall,
2005) remained unchanged (Figure 6d). Rac-specific inhibi-
tors (NSC23766 or EHT1864) showed strong inhibition of
Rac1 activity in vivo (Figure 6e) and significant inhibition of
allografts growth (Figure 6a) without inducing body-weight
loss (Supplementary Figure S5A online). Proliferation was
decreased by about 50% (Figure 6b). Consistent with Rac1
deletion results, both NSC23766- and EHT1864-treated
allografts showed a strong decrease in Pak2, Erk1/2, and
AKT activation (Figure 6e). Interestingly, analysis of vehicle-
treated mice systematically revealed pigmentation of left
axillary and inguinal skin-draining lymph nodes (Figure 6f
and Supplementary Figure S5B online), a characteristic of the
metastatic process. Tumor-draining lymph nodes were
enlarged (Figure 6f and g and Supplementary Figure S5B
online), and contained large numbers of dopachrome
tautomerase-positive pigmented proliferating melanocytic
cells (Figure 6h) and disrupted architecture (Supplementary
Figure S5C online). However, in tamoxifen, NSC23766- or
EHT1864-treated mice, lymph nodes retained their normal
architecture and weight (Figure 6f and g and Supplementary
Figure S5B, C online). All vehicle-treated mice (6/6) had
melanocytes in lymph nodes (Figure 6h and i, Supplementary
Figure S5C online). Whereas, none of mice (0/6) treated with
tamoxifen and only 1 in 4 mice treated with either NSC23766
or EHT1864 showed melanocytes in lymph nodes (Figure 6h
and i, Supplementary Figure S5C online). Together, these
data indicate that Rac1 activity is required for NRasQ61K-
induced tumor growth and lymph node spread in vivo, which
suggests that Rac1 may be a valid therapeutic target against
NRasQ61K-induced metastatic melanoma.
DISCUSSION
NRasQ61K does not affect either migration or proliferation
during embryogenesis nor compensate for Rac1 loss
As NRasQ61K is a major driver of human melanoma (Hendrix
et al., 2007), we investigated whether expression of NRasQ61K
would alter the growth, survival, or motility of melanoblasts
during embryogenesis. However, NRasQ61K-expressing em-
bryos showed a normal distribution and numbers of
melanoblasts until birth. Although we cannot formally
discount the possibility that NRasQ61K may enhance melano-
blast proliferation and simultaneously promote apopotosis,
we did not observe any apoptotic melanoblasts using live
ex vivo imaging (Supplementary Movie S1 online) or by
histology (not shown). This may indicate a high basal level of
NRas activity in melanoblasts during embryogenesis, as cells
are proliferating and populating the skin and that KitL (kit
ligand) is expressed in the embryo epidermis and decreases
after birth (Balch et al., 2011). Other factors besides Ras may
be limiting for the growth and accumulation of melanoblasts
such that expressing NRasQ61K does not further enhance
proliferation or survival. Melanoblasts require the membrane-
bound form of KitL for survival and migration in the
epidermis, suggesting cell–cell interactions might be involved
(Abraham et al., 2012). Rac1 has been shown to mediate the
formation of dendritic structures in melanoma cells in
response to melanocyte-stimulating hormone and UV light
in vitro (Scott and Cassidy, 1998; Balch et al., 2011).
However, whether dendritic structures mediated by Rac1 in
melanocytes or melanoma cells in vitro are analogous to long
protrusions mediated by Rac1 during melanoblast migration
in vivo is still not clear. We emphasize here that, in addition
to our previous study (Li et al., 2011), Rac1 is an important
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mediator of dynamic long protrusions, which contribute to
melanoblast migration in epidermis.
Rac1 is required for NRasQ61K-induced survival of dermal
melanocytes
Adult mice expressing NRasQ61K in the melanocyte lineage
accumulated more dermal and hair follicle melanocytes than
normal mice. Rac1 deletion in melanocytes of NRasQ61K-
expressing mice resulted in loss of dermal melanocytes
similar to normal mice, suggesting that Rac1 has a very
important role downstream of NRas in regulating melanocyte
survival in the dermis. However, we failed to detect any
apoptotic melanocytes in dermis with cleaved caspase-3
antibody in both P0.5 and P3 skin sections (data not shown).
Cells may be rapidly cleared or die via a non-apoptotic
mechanism.
c-Kit signaling triggers proliferation and survival via
activation of Ras via mitogen-activated protein kinase/
extracellular signal-–regulated kinase signaling (Mackenzie
et al., 1997) and PI3 kinase. KitL accumulates in the hair
bulbs of murine anagen hair follicles with very little or no
expression in the adult epidermis (Peters et al., 2003). Lack of
KitL survival signals in the epidermis after birth may explain
why in normal mice, melanocytes cannot survive in
epidermis. However, expression of activated NRasQ61K in
melanocytes may overcome the requirement for KitL and thus
promote melanocyte survival in epidermis in a Rac1-
dependent manner. It will be of interest to see whether the
Rac1 function can be compensated by ectopic expression
of KitL in epidermis (Kunisada et al., 1998) or by deleting
Rac1 in mice lacking the Ras-GAP Nf1 (McCalmont and
Bastian, 2012).
Rac1 is required for NRasQ61K-induced AIG and invasive
matrix-degrading capacity of melanocytes
Knockdown of Rac1 in melanoma cells resulted in defective
proliferation in vitro (Bauer et al., 2007) and Rac1 is
important downstream of KRasG12D in a lung cancer model
(Kissil et al., 2007). We explored the possibility that Rac1 was
required for AIG conferred by NRasQ61K on primary mouse
melanocytes in culture. NRasQ61K-expressing melanocytes
showed Rac1-dependent AIG (Figure 1). Survival of AIG may
be important for melanoblasts during their migration through
the dermis and epidermis. This could point to an importance
of Rac1 in melanoma development, progression, and meta-
static spread, as AIG may be important for these processes.
In addition to its contribution to AIG, Rac1 was surpris-
ingly important for invasive and matrix degradative capacity
of cultured melanocytes (Figure 5). Normal immortalized
melanocytes did not form invadopodia or degrade gelatin
matrix, but NRasQ61K-expressing melanocytes did so in a
Rac1-dependent manner (Yamaguchi et al., 2005; Linder,
2007). Rac1 has been previously implicated in invadopodia
using dominant negatives (Nakahara et al., 2003; Furmaniak-
Kazmierczak et al., 2007) but to our knowledge it has not
been previously reported that Rac1 is essential for invadopo-
dia and can work downstream of NRasQ61K in melanoma
cells. This has important implications for understanding how
Ras confers invasion potential on cells and raises the question
of which Rac1 targets are key in invadopodia formation.
Rac1 inhibition as potential therapy for melanoma
Finally, loss of Rac1 or its pharmacological inhibition halted
tumor growth in vivo and prevented metastatic spread,
suggesting that Rac1 is a key downstream effector of
NRasQ61K in melanoma tumor growth and progression. It
should be noted that although sentinel node biopsy is now
widely recommended for the staging of melanomas and has
proven prognostic value (Balch et al., 2011), some interesting
controversies remain. For example, two recent studies high-
light lymph node spread of an apparently benign melanocytic
nevus, raising the possibility that even in nevi that are not
genetically unstable, lymph node spread can occur (Abraham
et al., 2012; McCalmont and Bastian, 2012). However,
larger studies such as Balch et al. (2001) do identify lymph
node spread as a significant predictor of survival. In our
study, Rac1 loss or downregulation by treatment of mice with
Rac inhibitors NSC23766 or EHT1864 decreased key growth
signaling pathways via PAK2, AKT, and extracellular signal–-
regulated kinase, and slowed proliferation in tumors, as well
as halting lymph node spread. Thus, we propose that Rac1 is
an important candidate target for melanoma tumor growth
and metastasis downstream of NRas and targeting Rac1 or its
effectors could be effective therapies to pursue.
MATERIALS AND METHODS
Transgenic mice and genotyping
All experiments were performed according to UK Home Office
regulations. See also Supplemental Materials online.
Ex vivo imaging of melanoblast migration
Experimental setup was previously reported (Li et al., 2011).
Whole-mount staining and immunohistochemistry
Whole-mount staining of dopachrome tautomerase-LacZ-
positive mouse embryos and dorsal skin was previous reported
Figure 4. Expression of NRasQ61K does not affect melanoblast migration in epidermis. All experiments show embryo skin explants or embryos. (a) Combined Z-
stack confocal images of melanoblasts from Z/EG NRas and Z/EG Rac1 f/f NRas embryo skin. Long (Xcell body width) and short (pcell body width)
protrusions, are shown with white and yellow arrows, respectively. (b) Three hour tracks of melanoblasts. Black tracks migrated faster and red slower than
average of control (Ctr). (c) Live imaging of cell protrusion (yellow arrow) dynamics. (d) Live imaging of melanoblast in GFP-Lifeact NRas Ctr or GFP-Lifeact Rac1
f/f NRas skin. Yellow arrows indicate protrusions. (e) Migration speed. (f) Persistence. (g) Number of long/short protrusions per melanoblast. (h) Proportion of
melanoblasts with long/short protrusions. (i) Lifetime of growing protrusions. (j) Frequency of protrusion formation. (k) Photos and (l) quantification of
melanoblasts in E15.5 DCTHLacZ embryos. Melanoblasts are indicated with black arrows. Black dotted lines represent epi/dermal junction. Error bars indicate
mean±SEM. **Po0.01, by t-test. Bars (a, c)¼10 mm and (k) 20 mm.
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(Li et al., 2011). Immunohistochemistry was done with standard
methods (see Supplementary Material online).
Growth in soft agar
A total of 1 104 cells were plated in 1ml of 0.35% SeaPlaque
agarose/DMEM/10% fetal bovine serum (Lonza Rockland, Rockland,
ME) on top of 1.5ml of 0.7% SeaPlaque agarose/DMEM/10% fetal
bovine serum in 6-well dishes. Once solidified, the agarose was
covered with 2.5ml F-12/10% fetal bovine serum with or without
200 nM 12-O-tetradecanoylphorbol 13-acetate, which was changed
twice weekly. Images were captured 2 weeks later at room
temperature using Zeiss Stemi 2000C (Carl Zeiss, Welwyn Garden
City, UK) dissection microscope at  0.65 magnification. The
number of colonies (40.1mm in diameter) and the relative size of
colonies were determined 2 weeks after plating.
Fluorescent gelatin degradation assay
Gelatin degradation assay was done as previously described (Li
et al., 2010).
Cell culture
Primary mouse melanocytes were isolated from 1–day-old Rac1 f/f
Ink4a/ TyrHCreERT2þ /o (#3 and #4), TyrHNRasQ61Kþ /o Rac1 f/f
Ink4a/ TyrHCreERT2þ /o (#10 and #11), and TyrHNRasQ61Kþ /o
Rac1 f/f Ink4a/ TyrHCreERT2o/o littermate mice and cultured as
previously reported (Li et al., 2011).
Effector domain pulldown assay
The relative levels of GTP-bound Rac1 in tumors treated with vehicle
or Rac inhibitors (NSC23766 or EHT1864) were determined by
an effector pulldown assay as described previously (Vidali et al.,
2006).
Organotypic invasion assay
Organotypic cultures were set up as described (Edward et al., 2005).
See Supplementary Materials online for modifications.
Tumor transplantation and in vivo treatment studies
For tumor grafting experiments, #11 primary immortalized mouse
melanocytes cell line were introduced into mice by subcutaneous
injection ofB1 106 cells in 0.1ml. Phosphate-buffered saline into
the lower flank of mouse (CD-1 nude females 6-week-old, Charles
River Lab, Wilmington, MA). See also Supplementary Materials
online.
Assaying proliferation in vivo
Proliferation levels were assessed by measuring bromodeoxyuridine
(BrdU; Amersham Biosciences, Piscataway, NJ) incorporation. Mice
were injected with 250ml of BrdU 2hours before being killed.
Immunohistochemical staining for BrdU was then performed using
an anti-BrdU antibody (BD Bioscience, Oxford, UK). At least three
mice were used from each treatment for analysis.
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